UPCOMING SESSIONS in ET
Tue, Sep 8, 2026
5:00 – 6:00 AM Bangkok
Your First Mayo Clinic Evaluation: What to Expect and How to Prepare Cecelia Hernandez Click Here To Register
UPCOMING SESSIONS in ET
Tue, Sep 8, 2026 · 5:00 – 6:00 AM Bangkok
Your First Mayo Clinic Evaluation: What to Expect and How to Prepare
Cecelia Hernandez
Click Here To Register
View all sessions

News

science direct
May 25, 2026
Apical Hypertrophic Cardiomyopathy in ATTR Val142Ile Carrier: When Genes and Phenotype Diverge
AbstractBackgroundPathogenic transthyretin (TTR) variants, such as V142I, demonstrate incomplete, age-dependent penetrance and may be present in patients without…
Read more
Preprints.org
May 25, 2026
A Proof-of-Concept Multimodal Framework for Transthyretin Amyloidosis Classification from Clinical Narratives and ECG Images
AbstractTransthyretin amyloidosis (ATTR) is a rare, progressive, and fre- quently under-recognized systemic disease whose early clinical manifes- tations may…
Read more
attr-cmcompanion.
May 22, 2026
Coramitug obtains Fast Track designation for ATTR-CM
Prothena Biosciences announced that coramitug (previously PRX004) has received Fast Track designation for the treatment of transthyretin amyloid cardiomyopathy…
Read more
Rare Disease Advisor
May 22, 2026
Patients With ATTR-CM and Heart Failure Shown to Have Frequent Outpatient Clinic Visits
Older patients hospitalized due to heart failure in the US were cared for with frequent outpatient clinic visits before and after heart failure hospitalization,…
Read more
medscape
May 22, 2026
Loop Recorders Reveal Arrhythmias in Cardiac Amyloidosis
TOPLINE:In patients newly diagnosed with cardiac amyloidosis (CA), continuous rhythm monitoring using implantable loop recorders found that clinically significant…
Read more
medscape
May 22, 2026
Could Gene Editing Eventually Offer a ‘One-Time’ Treatment for CVD?
Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene…
Read more
globalcardiologyscienceandpractice
May 22, 2026
Clinical And Genetic Profile Of Hereditary Transthyretin (ATTRv) Amyloidosis In The Middle East: A Single-Center Report
AbstractBackground and Purpose: Transthyretin (ATTR) amyloidosis, including wild-type (ATTRwt) and hereditary (ATTRv) forms, is a rare but increasingly recognized…
Read more
amyloidosis
May 22, 2026
PREMIO SERAFINO MANSUETO | Heart failure with preserved ejection fraction and transthyretin cardiac amyloidosis: an Internal Medicine–led heart failure clinic as a key hub for early diagnosis and multidisciplinary care
Introduction. Heart failure (HF) is a leading cause of hospitalization in Internal Medicine and HF with preserved ejection fraction (HFpEF) accounts for…
Read more
amyloidosis
May 22, 2026
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2…
Read more
science direct
May 21, 2026
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B
AbstractBackgroundIn the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly…
Read more
Subscribe to